Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer

Status

Recruiting

NCT ID

NCT06398639

The goal of this clinical trial is to evaluate a screening method to detect clinically relevant prostate cancer. This clinical trial is using genetic data to determine a man's risk of cancer, together with multiparametric magnetic resonance imaging (mpMRI) to identify men with higher grade cancer.

The main questions it aims to answer are:

* If genetic data related to prostate cancer used with MRI can identify higher-grade, potentially fatal prostate cancer
* What age a MRI is useful clinically for prostate cancer screening
* If deep learning methods used with MRI when the genetic risk of the man is known can more accurately predict significant cancers

Participants will:

* Get a prostate specific antigen (PSA) blood test
* Get an mpMRI
* Get the results of their genetic data to determine if they are considered high-, intermediate-, or low-risk for prostate cancer based on the trials genetic testing
* Follow-up for this trial based on the participants risk and findings from the PSA test and mpMRI

Intervention

Polygenic Risk Score (PRS)

Condition

Prostate Cancer, Polygenic Risk Score

Investigators

Adam S Kibel, MD, MHCM, Peter Pinto, MD, Peter L Choyke, MD, FACR, Tamaro S Hudson, PhD, MPH, Pamela Coleman, MD, Peter A Pinto, MD, Gregory T Chesnut, MD, Ismail B Turkbey, MD

See list of participating sites